Climate change in Kenya is affecting millions of people who work outside. Farmers, construction workers, street vendors and schoolchildren now spend long hours in stronger sun and higher heat. Climate data from the Kenya Meteorological Department show a clear warming trend and some regions, especially the coast and parts of western Kenya, have warmed noticeably since records began. March, just before the rainy season, has shown some of the largest temperature rises and reduced cloud cover lets more ultraviolet radiation reach the ground.
Dermatologists warn that darker skin does not give full protection. Doctors report more skin problems such as melasma (dark facial patches), photoaging, sun allergies, fungal and bacterial infections, and some non-melanoma skin cancers. Bianca Tod notes that melanin offers some protection but not total defence, and sunscreen remains expensive for many casual workers.
Experts advise simple, affordable measures: wide-brimmed hats, long sleeves, shade and moisturisers like petroleum jelly, shea butter or coconut oil. Local groups plant trees and create shaded school areas while authorities work to improve data and health services.
Difficult words
- ultraviolet radiation — invisible sunlight rays that can harm skin
- melasma — dark patches that appear on people's faces
- photoaging — skin damage and ageing caused by sun
- melanin — natural skin pigment that gives colour
- sunscreen — cream or lotion that protects against sun
- moisturiser — product that adds or keeps skin moisturemoisturisers
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Which of the recommended measures would be easiest for people who work outside to use, and why?
- How can schools and local groups help children during stronger sun and higher heat?
- Sunscreen is expensive for many casual workers. What can authorities or communities do to help protect them?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
